Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan:36 Suppl 1:23-28.
doi: 10.1111/jdv.17402.

Management of immune-related adverse events in anti-PD-1-treated patients with advanced cutaneous squamous cell carcinoma

T Gambichler  1 , C H Scheel  1 , J Reuther  1   2 , L Susok  1
Affiliations
Review

Management of immune-related adverse events in anti-PD-1-treated patients with advanced cutaneous squamous cell carcinoma

T Gambichler et al. J Eur Acad Dermatol Venereol. 2022 Jan.

Abstract

Immune checkpoint inhibitors (ICI) have shown very promising results in the management of patients with inoperable or metastatic cutaneous squamous cell carcinoma (cSCC). However, ICI can cause a range of immune-related adverse events (irAEs) affecting a multitude of organs including skin, gastrointestinal tract, endocrine system, heart, lung, kidneys and the nervous system. In principle, clinical management irAEs does not change significantly with respect to the kind of cancer treated with ICI. However, advanced cSCC typically occurs in a clinically challenging patient population typically presenting with advanced age and/or significant comorbidities such as immunosuppression due to haematological malignancies and their respective treatment. Moreover, many patients with advanced cSCC are organ transplant patients taking immunosuppressants. As a consequence use of ICI per se and management of ICI-induced irAEs generates more complexity and difficulties in patients with cSCC compared to other entities. Here, we provide a brief review on the management of anti-programmed cell death protein 1-induced irAEs in patients with cSCC focusing on the characteristic clinical challenges present in this population.

PubMed Disclaimer

References

    1. Gambichler T, Susok L. Fortgeschrittene basalzell- und plattenepithelkarzinome der haut. Best Pract Onkol 2019; 6: 262-271.
    1. Migden MR, Khushalani NI, Chang ALS et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020; 21: 294-305.
    1. Maubec E, Boubaya M, Petrow P et al. Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas. J Clin Oncol 2020; 38: 3051-3061.
    1. Wessely A, Steeb T, Leiter U, Garbe C, Berking C, Heppt MV. Immune checkpoint blockade in advanced cutaneous squamous cell carcinoma: what do we currently know in 2020? Int J Mol Sci 2020; 21: 9300.
    1. Leiter U, Loquai C, Reinhardt L et al. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. J Immunother Cancer 2020; 8: e000897.

MeSH terms

Substances